Rockefeller Capital Management L.P. grew its stake in Catalent Inc (NYSE:CTLT) by 430.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,007 shares of the company’s stock after acquiring an additional 3,252 shares during the period. Rockefeller Capital Management L.P.’s holdings in Catalent were worth $217,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in Catalent by 205.8% during the 2nd quarter. Wells Fargo & Company MN now owns 1,528,009 shares of the company’s stock worth $82,833,000 after buying an additional 1,028,286 shares during the period. BlackRock Inc. increased its stake in Catalent by 7.9% during the 1st quarter. BlackRock Inc. now owns 13,918,974 shares of the company’s stock worth $564,971,000 after buying an additional 1,023,315 shares during the period. Lazard Asset Management LLC increased its stake in Catalent by 149.5% during the 1st quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock worth $30,085,000 after buying an additional 444,120 shares during the period. First Trust Advisors LP increased its stake in Catalent by 5,014.5% during the 2nd quarter. First Trust Advisors LP now owns 257,926 shares of the company’s stock worth $13,982,000 after buying an additional 252,883 shares during the period. Finally, Ironvine Capital Partners LLC purchased a new stake in Catalent during the 2nd quarter worth approximately $13,581,000. 99.94% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on CTLT shares. Morgan Stanley upped their target price on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 28th. UBS Group upped their target price on shares of Catalent to $64.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group raised shares of Catalent from a “hold” rating to a “buy” rating and increased their price objective for the company from $50.00 to $62.00 in a research report on Friday, June 21st. Finally, Robert W. Baird increased their price objective on shares of Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $57.14.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.03. Catalent had a net margin of 5.46% and a return on equity of 15.89%. The company had revenue of $725.70 million for the quarter, compared to the consensus estimate of $719.20 million. During the same period in the prior year, the firm posted $0.67 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Analysts forecast that Catalent Inc will post 1.81 EPS for the current year.
In other news, SVP Steven L. Fasman sold 4,053 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total value of $219,024.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Littlejohns sold 15,940 shares of the company’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $53.53, for a total transaction of $853,268.20. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: What is the float in trading stocks?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.